Jiangsu Leads Nation with 89 Clinical Trials in April 2026-VCBeat

Introduction: April Clinical Trial Report

Distribution of Clinical Trial Types

In April 2026, according to the [China Clinical Trials] database in the Pharma Intelligence Enterprise Edition, the CDE disclosed a total of registered drug clinical trials.493 itemsClinical Trial Registration. Among them,Clinical trials of chemical drugs account for the majority with 359 projects., biologics and traditional Chinese medicine accounted for 123 and 11 items respectively.

In terms of trial phases, the largest proportion is "Other" clinical trials, reaching 38.9%, with a total of 192 trials, and the majority of these trials are bioequivalence studies of chemical drugs. Next are "Phase 1" trials, with a total of 136 studies, while the numbers of Phase 2 and Phase 3 trials are 70 and 60, respectively. There are only 5 Phase 4 clinical trials.

Note: Due to the fact that the same clinical trial may belong to multiple clinical stages.Situation, so the above statistical number will be more than the total number of clinical trials.

Analysis of Drug Clinical Trial Varieties

In the top 10 list of drug clinical trial varieties registered with CDE in April 2026, "Finerenone Tablets" ranked first with 14 registered trials, all of which were bioequivalence clinical trials."Finerenone Tablets"The 14 clinical trials were sponsored by companies such as Yantai Luyin Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Zhejiang Huayi Pharmaceutical Co., Ltd., and Yangtze River Pharmaceutical Group Co., Ltd. The indications for these clinical trials were all targeted at "adult patients with chronic kidney disease associated with type 2 diabetes (with albuminuria) to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular death, and hospitalization due to heart failure." "Mirogabalin Besylate Tablets" ranked second with eight clinical trials, all of which were bioequivalence trials.

More detailed information,Please see the figure below for details.Or visit the enterprise version of Yaozhi Data [Clinical Trials in China] Query the database.

Note: Due to parallel situations, the above ranking may include more than 10 items.

PS：Reply to the PharmData WeChat Official Account backend [Clinical 2026], ObtainFull Report PDF Version。

Analysis of Drug Clinical Trial Application Units

In the CDE Drug Clinical Trial Sponsor Rankings for April 2026,"Qilu Pharmaceutical Co., Ltd." Ranks First with 7 Clinical Registration Trials"Qilu Pharmaceutical Co., Ltd." conducted seven trials covering clinical trials of six different varieties, including both new drug clinical trials and bioequivalence trials, specifically for "Finerenone Tablets, QLG1091, QLS1410 Tablets, QLS5212, Monosialotetrahexosylganglioside Sodium Injection," etc.; "Cisen Pharmaceutical Co., Ltd." ranked second with six registered clinical trials, all of which were bioequivalence trials.

Note: Due to the presence of ties, there may be more than 10 entries in the ranking above.

Analysis of Drug Clinical Trial Institutions

In the CDE drug clinical trial registration public announcement in April 2026, “Henan Zhonghui Cardiovascular Hospital"Cisen Pharmaceutical Co., Ltd. tops the list by leading 16 clinical trials, all of which are bioequivalence trials."

"Peking University Cancer Hospital" ranked second by leading 14 clinical trials, all of which were for new drug clinical trials.More detailed information,Please see the figure below for details.Or visitPharmcube Data Enterprise Edition [Clinical Trials in China] DatabaseConduct an inquiry.

Note: Due to the presence of ties, there may be more than 10 entries in the ranking above.

Distribution of Clinical Trial Provinces

In the CDE drug clinical trial registration public announcement in April 2026, the distribution of clinical trial provinces by region of the sponsor organization is shown in the figure below,Jiangsu Ranks First with 89 Clinical Trial Registrations, Shanghai and Zhejiang rank second and third, respectively. For more details, please see the figure below or visitPharmcube Data Enterprise Edition [Clinical Trials in China] DatabaseConduct a search.

Key Events in Clinical Trials

On April 1, Rongchang Bio自主研发的靶向PSMA和B7H3的双抗ADC药物RC288Approved by NMPA to conduct Phase I/IIa clinical trials for the treatment of advanced solid tumors, this isThe First Bispecific Antibody-Drug Conjugate (ADC) to Enter Clinical Stage。

During the same period, BeiGeneBG-C0979 for InjectionApproved for clinical use to treat advanced solid tumors. The drug targets ADAM9 and is followed by RC288.The Second ADAM9 ADC Approved for Clinical Trials in China。

On April 13, positive results from the Phase 3 RASolute 302 clinical trial were announced. Oral RAS(ON) multi-selective inhibitorDaraxonrasib（RMC-6236）For treated metastatic pancreatic cancer patients, the median overall survival increased from 6.7 months to 13.2 months compared to standard chemotherapy.60% Reduction in Mortality Risk。

On April 15, an oral anticancer drug targeting HER2CefatrizineApproved in China for second-line treatment of HER2-mutant non-small cell lung cancer.

On April 10, the world's first DLL3/CD3 bispecific antibodyTaladotinibApproved for marketing in China, for third-line treatment of small cell lung cancer.

Innovative Drug Marketing Application: In April, a total ofFive Class 1 Innovative Biological Products Submit Applications for Market Launch, setting a new record for the highest sales in a single month, including Sinopharm's IL-4Rα monoclonal antibody Ledejibartimab, etc.

Data Source:Pharmcube Data - Global/China Clinical Trial Database, Clinical Research Analysis System

PS：Reply to the Yaoke Data WeChat Official Account backend [Clinical 2026], ObtainFull Report PDF Version。

Disclaimer: This article is for informational purposes only and does not represent the views of this platform. This article is not a recommendation for treatment options. If you need guidance on treatment options,Please visit a regular hospital for treatment. If it involves the content, copyright, and other issues of the work, please leave a message on this platform, and we will verify and handle it in the first time.

Editorial Responsibility | Xiao Er

Typesetting Design | Xiao Bai

Reprint Authorization | Teacher Chen 17308362010 (Same as WeChat)

Related tags:Clinical Drug Trials 0 0